# US 2012/0252781 A1 · Benzodiazepine Bromodomain Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252781 A1
- Document ID: US20120252781A1
- Status: Published application
- Kind: A1
- Application number: 13/504,971
- Filed: 2010-11-03
- Published: 2012-10-04
- Earliest claimed: 2009-11-05
- Assignees: GlaxoSmithKline LLC
- Inventors: James Bailey; Romain Luc Marie Gosmini; Olivier Mirguet; Jason Witherington
- Web page: https://patentgrep.com/patent/US20120252781A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

## Claims

### Claim 1

A compound of formula (I) or a salt thereof
where
R1 is C1-3alkyl;
R2 is —NR2aR2a′ or —OR2b;
wherein one of R2a or R2′a is hydrogen, and R2b or the other of R2a or R2′a is selected from C1-6alkyl, haloC1-6alkyl, R2cR2′cN—C1-6alkyl, carbocyclyl, carbocyclylC1-4alkyl, heterocyclyl and heterocyclylC1-4alkyl,
wherein any of the carbocyclyl or heterocyclyl groups are optionally substituted by one or more groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, carbonyl, —CO-carbocyclyl, azido, amino, hydroxyl, nitro and cyano, wherein the —CO-carbocyclyl group may be optionally substituted by one or more groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, azido, nitro and cyano;
or two adjacent groups on any of the carbocyclyl or heterocyclyl groups together with the interconnecting atoms form a 5- or 6-membered ring which ring may contain 1 or 2 heteroatoms independently selected from O, S and N;
or R2a and R2′a together with the N-atom to which they are attached form a 4-, 5-, 6- or 7-membered ring which optionally contains 1 or 2 heteroatoms independently selected from O, S and N; wherein the 4-, 5-, 6- or 7-membered ring is optionally substituted by C1-6alkyl, hydroxyl or amino;
R2c and R2′c are independently hydrogen or C1-6alkyl;
each R3 is independently selected from hydrogen, hydroxyl, halo, C1-6alkyl, halo C1-6alkyl, C1-6alkoxy, halo C1-6alkoxy, nitro, cyano, CF3, —OCF3, —COOR5, —C1-4alkylNR6R7 and —C1-4alkylOH;
R4 is hydroxyl, halo, C1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, nitro, cyano, CF3, —OCF3, —COOR5; or —OS(O)2C1-4alkyl;
R5 is C1-3alkyl; and
n is an integer 1 to 5.

### Claim 2 (depends on 1)

A compound or a salt thereof according to claim 1, wherein R1 is methyl.

### Claim 3 (depends on 1)

A compound or a salt thereof according to claim 1, wherein R2 is —OR2b and wherein R2b is C1-6alkyl.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

A compound or a salt thereof according to claim 1, wherein R2 is —NR2aR2a′.

### Claim 7 (depends on 6)

A compound or a salt thereof according to claim 6, wherein R2a is hydrogen and R2′a is C1-6alkyl.

### Claim at position 7

8-9. (canceled)

### Claim 10 (depends on 6)

A compound or a salt thereof according to claim 6 wherein R2′a is selected from R2cR2′cN—CH2—, R2cR2′cN—CH2CH2—, R2cR2′cN—CH2CH2CH2— and R2cR2′cN—CH2CH2CH2CH2—, and wherein R2c and R2′c are selected from hydrogen and methyl.

### Claim at position 9

11-13. (canceled)

### Claim 14 (depends on 6)

A compound or a salt thereof according to claim 6, wherein R2a is hydrogen and R2′a is selected from:

### Claim at position 11

15-16. (canceled)

### Claim 17 (depends on 6)

A compound or a salt thereof according to claim 6, wherein R2a is hydrogen and R2′a is selected from heterocyclyl-CH2—, heterocyclyl-CH2CH2—, heterocyclyl-CH2CH2CH2— and heterocyclyl-CH2CH2CH2CH2—, wherein the heterocyclyl is selected from:

### Claim at position 13

18-24. (canceled)

### Claim 25 (depends on 1)

A compound or a salt thereof according to claim 1, wherein R4 is 8-MeO.

### Claim 26 (depends on 1)

A compound or a salt thereof according to claim 1 wherein the chiral carbon atom depicted by * is the S-enantiomer.

### Claim 27 (depends on 1)

A compound or a salt thereof according to claim 1 which is any one of Examples 1-82 or a salt thereof.

### Claim at position 17

28-30. (canceled)

### Claim 31

A compound which is 2-[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide
or a salt thereof.

### Claim 32

(canceled)

### Claim 33 (depends on 31)

A pharmaceutical composition which comprises a compound or a salt thereof according to claim 31 and one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 34 (depends on 31)

A combination pharmaceutical product comprising a compound or a salt thereof according to claim 31 together with one or more other therapeutically active agents.

### Claim at position 22

35-39. (canceled)

### Claim 40 (depends on 31)

A method for treatment of a disease or condition, for which a bromodomain inhibitor is indicated, in a subject in need thereof which comprises administering a therapeutically effective amount of compound or a salt thereof according to claim 31.

### Claim 41 (depends on 40)

A method for treatment according to claim 40, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.

### Claim 42 (depends on 40)

A method for treatment according to claim 40, wherein the disease or condition is cancer.

### Claim 43 (depends on 40)

A method for treatment according to claim 40, wherein the subject is a human.

### Claim 44 (depends on 31)

A method for inhibiting a bromodomain which comprises contacting the bromodomain with a compound or a salt thereof according to claim 31.
